Skip to main content

Consider acne severity and potential risks when treating acne vulgaris in pregnant and breastfeeding women

Abstract

Acne vulgaris is a common skin condition in pregnant women. The choice of medication depends on the severity of the acne and the potential risks of the treatment. As a general rule, topical agents are safer than oral agents and should be the first choice, with oral agents and/or blue–violet or red light phototherapy considered as second-line treatments. The use of hormonal therapies, oral and topical retinoids and certain antibacterials should be avoided.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. Drugs. 2013;73(8):779–87.

    CAS  PubMed  Article  Google Scholar 

  2. Meredith FM, Ormerod AD. The management of acne vulgaris in pregnancy. Am J Clin Dermatol. 2013;14(5):351–8.

    PubMed  Article  Google Scholar 

  3. US FDA pregnancy categories. http://depts.washington.edu/druginfo/Formulary/Pregnancy.pdf. Accessed 5 Aug 2013.

  4. American Academy of Pediatric Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776.

    Google Scholar 

  5. US National Library of Medicine. Drugs and lactation database. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. Accessed 8 Aug 2013.

  6. Bozzo P, Chua-Gocheco A, Einarson A. Safety of skin care products during pregnancy. Can Fam Phys. 2011;57(6):665–7.

    Google Scholar 

  7. Hale EK, Pomeranz MK. Dermatologic agents during pregnancy and lactation: an update and clinical review. Int J Dermatol. 2002;41(4):197–203.

    PubMed  Article  Google Scholar 

  8. Galderma (UK) Ltd. Rozex cream (metronidazole Ph. Eur 0.75% w/w): summary of product characteristics. 2012. http://www.medicines.org.uk/emc/medicine/700/SPC/Rozex+Cream/. Accessed 6 Aug 2013.

  9. Tuffanelli DL. Successful pregnancy in a patient with dermatitis herpetiformis treated with low-dose dapsone. Arch Dermatol. 1982;118(11):876.

    CAS  PubMed  Article  Google Scholar 

  10. Sanders SW, Zone JJ, Foltz RL, et al. Hemolytic anemia induced by dapsone transmitted through breast milk. Ann Intern Med. 1982;96(4):465–6.

    CAS  PubMed  Article  Google Scholar 

  11. Webster GF. Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? J Drugs Dermatol. 2010;9(5):532–6.

    PubMed  Google Scholar 

  12. Trivedi NA. A meta-analysis of low-dose aspirin for prevention of preeclampsia. J Postgrad Med. 2011;57(2):91–5.

    CAS  PubMed  Article  Google Scholar 

  13. Panchaud A, Csajka C, Merlob P, et al. Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study. J Clin Pharmacol. 2012;52(12):1844–51.

    CAS  PubMed  Article  Google Scholar 

  14. Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A. 2005;136(2):117–21.

    PubMed  Article  Google Scholar 

  15. Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin. 2006;24:167–97.

    CAS  PubMed  Article  Google Scholar 

  16. Feneran AN, Kaufman WS, Dabade TS, et al. Retinoid plus antimicrobial combination treatments for acne. Clin Cosmet Investig Dermatol. 2011;4:79–92.

    CAS  PubMed Central  PubMed  Google Scholar 

  17. Källén BA, Otterblad Olausson P, Danielsson BR BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol. 2005;20(2):209–14.

    PubMed  Article  Google Scholar 

  18. Mays RM, Gordon RA, Wilson JM, et al. New antibiotic therapies for acne and rosacea. Dermatol Ther. 2012;25(1):23–37.

    PubMed  Article  Google Scholar 

  19. Sorensen HT, Skriver MV, Pedersen L, et al. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis. 2003;35:104–6.

    CAS  PubMed  Article  Google Scholar 

  20. Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ. 2011;183(16):1851–8.

    PubMed Central  PubMed  Article  Google Scholar 

  21. Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation. 5th ed. Baltimore: Williams & Wilkins; 1998.

    Google Scholar 

  22. Harmon T, Burkhart G, Applebaum H. Perforated pseudomembranous colitis in the breast-fed infant. Pediatr Surg. 1992;27(6):744–6.

    CAS  Article  Google Scholar 

  23. Katsambas A, Dessinioti C. New and emerging treatments in dermatology: acne. Dermatol Ther. 2008;21(2):86–95.

    CAS  PubMed  Article  Google Scholar 

  24. Dréno B, Blouin E. Acne, pregnant women and zinc salts: a literature review. Ann Dermatol Venereol. 2008;135(1):27–33.

    PubMed  Article  Google Scholar 

  25. Martínez-Frías ML, Bermejo E, Rodríguez-Pinilla E, et al. Periconceptional exposure to contraceptive pills and risk for Down syndrome. J Perinatol. 2001;21(5):288–92.

    PubMed  Article  Google Scholar 

Download references

Disclosure

This article was adapted from Drugs 2013;73(8):779–87 [1]. The preparation of these articles was not supported by any external funding.

Author information

Authors and Affiliations

Consortia

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Adis Medical Writers. Consider acne severity and potential risks when treating acne vulgaris in pregnant and breastfeeding women. Drugs Ther Perspect 30, 16–20 (2014). https://doi.org/10.1007/s40267-013-0092-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-013-0092-2

Keywords

  • Acne
  • Isotretinoin
  • Benzoyl Peroxide
  • Roxithromycin
  • Azelaic Acid